This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Meiji Seika Pharma Co., Ltd., Nichiban Co., Ltd., Nichiban Company Limited. Active years: 2018-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2018-2026
Title: Kyohei Matsuo: Innovator in Dermatological Treatments
Introduction
Kyohei Matsuo is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of dermatology through his innovative inventions. His work primarily focuses on developing effective treatments for skin conditions.
Latest Patents
Matsuo holds a patent for a patch designed to treat dermatophytosis. This patch includes a pressure-sensitive adhesive layer that contains an acrylic-based pressure-sensitive adhesive and 2-(3, 5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol or a salt thereof. The acrylic-based pressure-sensitive adhesive is formulated with a copolymer of 2-ethylhexyl acrylate and N-vinylpyrrolidone, with a mass ratio of 70:30 to 90:10.
Career Highlights
Throughout his career, Kyohei Matsuo has worked with prominent companies such as Meiji Seika Pharma Co., Ltd. and Nichiban Company Limited. His experience in these organizations has contributed to his expertise in developing innovative solutions for dermatological issues.
Collaborations
Matsuo has collaborated with several professionals in his field, including Koji Kawahara and Noriko Kan. These partnerships have enhanced his research and development efforts, leading to successful innovations.
Conclusion
Kyohei Matsuo is a distinguished inventor whose work in dermatological treatments has made a significant impact. His innovative patch for treating dermatophytosis exemplifies his commitment to improving healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile